573704-64-0

Usage

Uses

Used in Pharmaceutical Industry:
(3S)-3-Pyrrolidinecarboxamide is used as a pharmaceutical compound for its potential therapeutic properties, offering promising avenues for future research and development in medicine.
Used in Medical Research:
In the field of medical research, (3S)-3-Pyrrolidinecarboxamide is utilized for exploring its interactions with biological systems, which may contribute to the discovery of new treatments and therapies.
Used in Biochemistry:
(3S)-3-Pyrrolidinecarboxamide serves as a biochemical tool, aiding in the study of biological processes and mechanisms, potentially leading to advancements in understanding and manipulating these systems.
Used in Chemical Research:
As a chemical compound, (3S)-3-Pyrrolidinecarboxamide is used in chemical research to investigate its properties, reactivity, and potential applications in various chemical processes and syntheses.

InChI:InChI=1S/C5H10N2O/c6-5(8)4-1-2-7-3-4/h4,7H,1-3H2,(H2,6,8)/t4-/m0/s1

Upstream product

• 193693-69-5 (+)-(S)-3-cyanopyrrolidine-1-carboxylic acid benzyl ester 
• 573704-57-1 (+)-(S)-3-carbamidopyrrolidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

Synthesis of potent oxindole CDK2 inhibitors

A series of oxindole CDK2 inhibitors was synthesized. These novel analogues have a saturated monosubstituted cyclic moiety at their C-4 position that mimics the ribofuranoside of ATP. This substitution afforded agents with increased potency relative to th